- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
Détention brevets de la classe A61K 39/04
Brevets de cette classe: 1072
Historique des publications depuis 10 ans
|
78
|
74
|
68
|
63
|
67
|
59
|
47
|
64
|
52
|
20
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1598 |
30 |
| Access to Advanced Health Institute | 76 |
22 |
| International AIDS Vaccine Initiative, Inc. | 63 |
21 |
| Longhorn Vaccines and Diagnostics, LLC | 92 |
19 |
| Statens Serum Institut | 86 |
18 |
| Vakzine Projekt Management GmbH | 29 |
18 |
| Wisconsin Alumni Research Foundation | 3920 |
17 |
| Altor BioScience, LLC | 78 |
16 |
| The Regents of the University of California | 20574 |
15 |
| Rutgers, The State University of New Jersey | 1956 |
15 |
| The Johns Hopkins University | 5825 |
14 |
| Immodulon Therapeutics Limited | 42 |
14 |
| Institut Pasteur | 787 |
13 |
| The General Hospital Corporation | 4827 |
12 |
| Infectious Disease Research Institute | 44 |
12 |
| Albert Einstein College of Medicine, Inc. | 590 |
11 |
| Archivel Farma, S.L. | 12 |
10 |
| The UAB Research Foundation | 658 |
10 |
| BioNTech SE | 778 |
10 |
| The Trustees of the University of Pennsylvania | 4406 |
9 |
| Autres propriétaires | 766 |